Eris Lifesciences posts 14.5% rise in Q1 FY27 PAT to Rs 143 crore as insulin and GLP-1 launch lifts growth
AI Market Summary
Eris Lifesciences reported FY27 Q1 consolidated PAT up 14.5% YoY on 13% revenue growth, led by domestic branded formulations, insulin share gains, and a strong GLP-1 launch (Sundae). Margin compression reflects a higher biologics mix, while Swiss Parenterals faces EU compliance remediation. The results reinforce execution in diabetes/obesity therapies but are mainly single-stock relevant, with limited broader market spillover.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.31%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Eris Lifesciences reported consolidated profit after tax of Rs 143 crore in the first quarter of FY27, up 14.5% year on year, while revenue from operations rose 13% to Rs 873 crore. The company said the performance was driven by growth in its domestic branded formulations business, continued market-share gains in insulin therapies, and a strong launch for its GLP-1 brand, Sundae. It also highlighted traction in semaglutide, with Sundae taking around 21% prescription share and nearly 20% unit share by June 2026.
